• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Methadone
  • Buprenorphine
  • Patient Brochures
  • Events

Relative Costs and Benefits of Methadone vs. Buprenorphine in OUD

October 11, 2019 by Barbara Goodheart, ELS

It’s generally accepted that medication-assisted treatment (MAT) with methadone or buprenorphine is more effective than nonpharmacologic treatment in opioid use disorder (OUD).

But what about the relative merits of methadone and buprenorphine in OUD? Important differences exist between the two medications in several key areas: underlying pharmacologic actions, dosing schedule, treatment-related resources needed, and costs of treatment, “making it important for all stakeholders to understand the relative costs and benefits of each,” according to the authors of a study recently published in the Journal of Substance Abuse Treatment.

“A Comparison of Adherence, Outcomes, and Costs Among Opioid Use Disorder Medicaid Patients Treated With Buprenorphine and Methadone: A View From the Payer Perspective,” begins with a summary of what is known, or postulated, about the two medications:

Methadone Buprenorphine
Schedule II; resource-intensive; dispensed only in licensed/accredited OTPs Schedule III; more accessible to rural patients; available through primary care physicians or waivered physician extenders
Some evidence: more likely than buprenorphine to retain patients in treatment and/or prevent relapse Some evidence: patients more likely to relapse, or have shorter treatment episodes, than methadone patients
Patients are slightly more likely to have a drug-related overdose, especially initially Programs spend fewer health care dollars, use fewer health care resources

Lead author Suzanne Kinsky, MBA, PhD, and her team of investigators, most of whom are affiliated with the University of Pittsburgh Medical Center (UPMC), were especially interested in the comparative performance of methadone and buprenorphine in three critical areas:

  • Reducing the use of illicit opioids
  • Reducing the risk of drug-related overdose (OD)
  • Lowering overall health care costs

They assessed “adherence, costs, and emergency department (ED) nonfatal drug-related overdose outcomes” among a sample of Medicaid members, examining the data from the payer perspective.

Study Group

Enrollees were Pennsylvania residents covered by Medicaid, the primary funding source for MAT in the geographic area. Enrollees also received physical and behavioral coverage through the UPMC Health Plan.

The authors set up protocols for two analyses—adherence and cost—and selected study group enrollees. Using six months of physical and behavioral Medicaid claims data for newly treated patients, the authors looked at:

  • Predictors of adherence
  • Differences in adherence between methadone and buprenorphine
  • Relationship of adherence to nonfatal drug-related overdose in the ED
  • Total cost of care, methadone vs. buprenorphine

Results

Adherence Analysis

The team used the Area Deprivation Index (ADI) to assess adherence. The ADI is a composite of socioeconomic factors; high ADI values indicate areas of high socioeconomic deprivation.

Participants,
Adherence Analysis
Available for analysis:     1,184
Received buprenorphine:  972
Received methadone:       212
Definitions of Nonadherence

  • To methadone: a lapse in daily clinic visits of greater than seven days
  • To buprenorphine: a gap in medication coverage of more than 10 consecutive days

Key Findings

  • Only 3.6% of adherent individuals (either treatment) had a nonfatal, drug-related OD in the ED, vs. 13.2% of nonadherent individuals
  • Six-month adherence was higher with methadone (49.1%) than with buprenorphine (40.8%), but the difference was not statistically significant

Additional Findings

  • A nonfatal ED overdose
    • Was less likely in older people, women, and subjects who had adhered for six months*
    • Was more common in those who were nonadherent for six months*
  • Risk of nonadherence was lower in older individuals and in women*

(In this article, results reported with an asterisk are statistically significant (P ≤ 0.05); results reported without an asterisk do not reach the level of statistical significance.)

Cost Analysis

The “cost of care” represents UPMC’s actual payments. The authors explained that cost was calculated “on a per member per month (PMPM) basis, and covered medical care, behavioral health care, and pharmacy costs.”

Participants,
Cost Analysis
Available for analysis: 692
Received methadone: 125
Received buprenorphine: 567

Key Findings

  • Although no difference in PMPM was seen between the two treatments, pharmacy costs decreased by $23 in those receiving methadone, but increased by $219 in those receiving buprenorphine*
  • In individuals receiving methadone
    • PMPM increased markedly—$1,173.50 from baseline—in nonadherent subjects*
    • PMPM decreased by $13.27 in adherent subjects*
  • In the buprenorphine group
    • PMPM increased by $533.20 in adherent subjects*
    • PMPM increased by $475.94 nonadherent subjects*

Additional Findings

  • In areas with low socioeconomic deprivation, six-month adherence was higher in the methadone group (55%) than in the buprenorphine group (40%)

Authors’ Comments

Although overdose occurred more than 3.5 times as often in participants who were nonadherent, the authors note that the design of the study “cannot rule out important sources of bias.” An example would be unobserved factors leading the individual to stay in treatment and follow safer ways of using opioids. They also cite “conflicting results” that highlight the challenge of measuring and controlling for contextual factors related to opioid use.

Adherence, overdose, and cost. Regarding adherence, there was no difference between methadone and buprenorphine from an overdose standpoint. But from a cost standpoint, the consequences of nonadherence were striking for individuals in the methadone group.

Factors influencing adherence. Adherence to MAT—regardless of treatment group—was a crucial factor. The authors recommended that when considering opioid interventions, health care providers and policy makers weigh factors that can influence adherence—such as age, gender, and neighborhood.

How to effectively address barriers to adherence is an issue that needs investigation, the authors point out, given the “profound and multi-level consequences of nonadherence.” In addition to behavioral and structural interventions, future studies could examine long-acting forms of buprenorphine and their effect on adherence, overdose, and costs.

Conclusion

In closing, the authors noted the need for comparative research on available therapies “so that individuals affected by opioid use, providers, payers, policymakers, and other stakeholders can make informed decisions about appropriate interventions. This study finds that there are complex relationships between MAT adherence, risk of nonfatal overdose, and cost of care.”

Reference

Kinsky S, Houck PR, Mayes K, et al. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective [Epub ahead of print May 31, 2019]. J Subst Abuse Treat. 2019;104:15-21. doi: 10.1016/j.jsat.2019.05.015

Filed Under: 2019, 30-5, Newsletter

Primary Sidebar

Upcoming Events

CADCA 2023 Leadership Forum and SAMHSA’s Prevention Day
January 30-February 3, 2023

Washington, D.C.
http://cadca.org/forum2023

2023 Rx and Illicit Drug Summit
April 10-13, 2023

Atlanta, Georgia
https://www.rx-summit.com/

2023 ASAM conference
April 13-16, 2023

Washington, D.C.
https://annualconference.asam.org/

 

View More Upcoming Events…

ATForum.com

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Federal Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

Sign up for News!

© 2023 Addiction Treatment Forum · All Rights Reserved